血清抗苗勒管激素检测替代多囊卵巢形态对多囊卵巢综合征诊断及表型分类的影响
单中心回顾性研究比较标准鹿特丹分类与两种修改版(单用血清抗苗勒管激素或联合超声定义多囊卵巢形态)对多囊卵巢综合征诊断及表型分布的影响。联合定义诊断多囊卵巢综合征的患者数(n=639)多于单用超声(n=612)或单用抗苗勒管激素(n=601),且表型B几乎消失。
要点
- 联合超声和血清抗苗勒管激素定义多囊卵巢形态可诊断更多多囊卵巢综合征患者。
- 联合定义下多囊卵巢形态在639例中637例被识别,表型B几乎消失。
- 超声与抗苗勒管激素对多囊卵巢形态不一致者103例(16.1%),其中单用超声9%、单用抗苗勒管激素7.1%。
核心结论
- 联合超声和血清抗苗勒管激素定义多囊卵巢形态诊断多囊卵巢综合征的患者数多于单用任一指标。
- 作者认为理想情况下应整合超声数据和血清抗苗勒管激素水平来定义鹿特丹分类中的多囊卵巢形态。
- 从成本效益角度,选择任一指标对多囊卵巢综合征诊断和表型影响不大。
研究设计与样本
- 单中心回顾性研究,数据来自2009年1月至2016年1月因稀发排卵和/或高雄激素血症转诊患者的前瞻性收集临床、实验室和超声数据库。
- 比较标准鹿特丹分类与两种修改版:单用血清抗苗勒管激素或联合(和/或)超声定义多囊卵巢形态。
主要发现
- 联合定义多囊卵巢形态诊断多囊卵巢综合征n=639,多于单用超声标准定义n=612和单用抗苗勒管激素n=601。
- 联合定义下639例中637例识别出多囊卵巢形态,表型B几乎消失。
- 超声与抗苗勒管激素对多囊卵巢形态不一致103例(16.1%),其中单用超声9%、单用抗苗勒管激素7.1%,P=0.159。
- 单用超声阳性比例在表型D中显著高于表型A(14.1% vs 5.8%,P<0.05)。
- 不一致病例中,单用抗苗勒管激素组血浆LH水平显著高于一致组,单用超声组空腹胰岛素血清水平倾向于更高。
关键数值与推荐
- 多囊卵巢综合征表型定义:A(完全表型,稀发排卵+高雄激素血症+多囊卵巢形态)、B(稀发排卵+高雄激素血症)、C(高雄激素血症+多囊卵巢形态)、D(稀发排卵+多囊卵巢形态)。
临床怎么用
- 作者认为理想情况下应整合超声数据和血清抗苗勒管激素水平来定义鹿特丹分类中的多囊卵巢形态。
局限性
- 本研究为回顾性研究。
- 转诊偏倚解释了表型D患者比例相对较高(28%)。
- 多囊卵巢形态由内部阈值定义。
- 所用抗苗勒管激素检测已不再市售。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does the use of the serum anti-Müllerian hormone (AMH) assay to replace or complement ultrasound (U/S) affect the diagnosis or phenotypic distribution of polycystic ovary syndrome (PCOS)? SUMMARY ANSWER: Combining U/S and the serum AMH assay to define polycystic ovarian morphology (PCOM) diagnoses PCOS (according to the Rotterdam classification) in more patients than definitions using one or the other of these indicators exclusively. WHAT IS KNOWN ALREADY: Since 2003, PCOM, as defined by U/S, is one of the three diagnostic criteria for PCOS. As it is closely correlated with follicle excess seen at U/S, an excessive serum AMH level could be used as a surrogate for PCOM. STUDY DESIGN, SIZE, DURATION: Single-center retrospective study from a database of prospectively collected clinical, laboratory and ultrasound data from patients referred for oligo-anovulation (OA) and/or hyperandrogenism (HA) between January 2009 and January 2016. PARTICIPANTS/MATERIALS, SETTING, METHOD: The standard Rotterdam classification for PCOS was tested against two modified versions that defined PCOM by either excessive serum AMH level alone (AMH-only) or a combination (i.e. 'and/or') of the latter and U/S. The PCOS phenotypes were defined as A (full phenotype, OA+HA+PCOM), B (OA+HA), C (HA+PCOM) and D (OA+PCOM). MAIN RESULTS AND THE ROLE OF CHANCE: PCOS was more frequently diagnosed when PCOM was defined as the combination 'positive U/S' and/or 'positive AMH' (n = 639) than by either only U/S-only (standard definition, n = 612) or by AMH-only (n = 601). With this combination, PCOM was recognized in 637 of the 639 cases that met the Rotterdam classification, and phenotype B practically disappeared. In this population, U/S and AMH markers were discordant for PCOM in 103 (16.1%) cases (9% U/S-only, 7.1% AMH-only, P = 0.159). The markers used had no other significant impact on the phenotypic distribution (except for phenotype B). However, the percentage of cases positive by U/S-only was significantly higher in phenotype D than in phenotype A (14.1% vs. 5.8%, P < 0.05). Furthermore, in the discordant cases, plasma LH levels were significantly higher in the AMH-only group than in the concordant cases, and fasting insulin serum levels tended to be higher in the U/S-only group. LIMITATIONS, REASONS FOR CAUTION: This is a retrospective study. A referral bias explains the relatively high proportion of patients with phenotype D (28%). PCOM was defined by in-house thresholds. The AMH assay used is no longer commercially available. WIDER IMPLICATIONS OF THE FINDINGS: Our results suggest that ideally both U/S data and serum AMH level should be integrated to define PCOM in the Rotterdam classification. In a cost-effectiveness approach, the choice of one or the other has little impact on the diagnosis and the phenotyping of PCOS. STUDY FUNDING/COMPETING INTEREST(S): No external funding. The authors have no conflict of interest to declare.
引用
- Fraissinet A, Robin G, Pigny P, et al. Use of the serum anti-Müllerian hormone assay as a surrogate for polycystic ovarian morphology: impact on diagnosis and phenotypic classification of polycystic ovary syndrome. Hum Reprod. 2017. PMID: 28854589. doi:10.1093/humrep/dex239
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。